Results 201 to 210 of about 4,575,740 (255)

Fragility of precision: resistance to mutant p53 reactivation. [PDF]

Signal Transduct Target Ther
Joerger AC, Stiewe T.
europepmc   +1 more source

The regulation of tumor suppressor protein, p53, and estrogen receptor (ERα) by resveratrol in breast cancer cells. [PDF]

Genes Cancer, 2016
Saluzzo J, Hallman KM, Aleck K, Dwyer B, Quigley M, Mladenovik V, Siebert AE, Dinda S.   +7 more
europepmc   +1 more source

Narrative review-the emerging role, functions, and mechanisms of UFMylation in cancers. [PDF]

Transl Cancer Res
Fang L, Yang F.
europepmc   +1 more source

The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERα) in breast cancer cells. [PDF]

Breast Cancer (Dove Med Press), 2017
Hallman K, Aleck K, Dwyer B, Lloyd V, Quigley M, Sitto N, Siebert AE, Dinda S.   +7 more
europepmc   +1 more source

Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. [PDF]

Sci Adv
Zhang X, Hao Q, Yang W, Yu Y, Yan Q, Wu Z, Hu Z, Zhou X, Wang J.   +8 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Cooperation or Conflict? Molecular and Physiological Cross-Talk Between the Aryl Hydrocarbon and Vitamin D Receptors. [PDF]

Pharmaceuticals (Basel)
Alqahtani MA.
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Anticancer effects of tangeretin associated with reactive oxygen species generation, mitochondrial dysfunction and apoptosis in CaSki cells. [PDF]

Oncol Rep
Ahn SH, Bhutta ZA, Na H, Lee HK, Choi KC.   +4 more
europepmc   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source